{"nctId":"NCT03753113","briefTitle":"Evaluating the Topical Herbal Solution on the Treatment of Male Pattern Hair Loss and Comparison With Minoxidil 5%","startDateStruct":{"date":"2018-11-28","type":"ACTUAL"},"conditions":["Androgenetic Alopecia"],"count":24,"armGroups":[{"label":"Treatment group","type":"EXPERIMENTAL","interventionNames":["Drug: Topical Herbal Solution","Drug: Topical Minoxidil 5%"]},{"label":"Control group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Topical Minoxidil 5%"]}],"interventions":[{"name":"Topical Herbal Solution","otherNames":[]},{"name":"Topical Minoxidil 5%","otherNames":["Minoxidil"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men 18 to 50 years old\n* Written consent\n* Normal general health status\n* Men who have a presentation of androgenetic alopecia (Norwood II - V).\n\nExclusion Criteria:\n\n* Use of any topical product in the target region interfering with the study product in the last three months\n* Within the past 6 months receiving of chemotherapy/cytotoxic agents\n* Clinical diagnosis of alopecia areata or other non-AGA forms of alopecia\n* Uncontrolled hypertension\n* Any dermatological disorders in the scalp, such as fungal or bacterial infections, eczema, atopic dermatitis, seborrheic dermatitis, psoriasis, sun damage, skin cancer\n* Hormonal diseases such as thyroid disorders, diabetes and, ...\n* Smokers\n* Liver and kidney disease\n* History of hair transplants\n* History of surgical correction of hair loss on the scalp\n* Subject having dyed, bleached hair or, with a permanent wave prior to study start.\n* No written consent","healthyVolunteers":true,"sex":"MALE","genderBased":true,"genderDescription":"Healthy men 18 to 50 years old","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hair Diameter","description":"Change in hair diameter over time as compared to Baseline. Hair diameter measured via a digital micrometer.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.42","spread":"8.88"},{"groupId":"OG001","value":"51.58","spread":"7.67"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.92","spread":"7.35"},{"groupId":"OG001","value":"51.17","spread":"7.82"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.67","spread":"7.19"},{"groupId":"OG001","value":"50.58","spread":"7.38"}]}]}]},{"type":"SECONDARY","title":"Patients Self - Assessment Questionnaire","description":"Self-administered hair growth questionnaire, consisting of 4 questions in the patient's language on treatment efficacy and three questions on satisfaction with appearance. For differences between self-assessment questionnaires. This questionnaire following 5-point scale: 1 = very satisfied, 2 = satisfied, 3 = neutral (neither satisfied nor dissatisfied), 4 = dissatisfied, 5 = very dissatisfied. Higher scores indicated a worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"0.452"},{"groupId":"OG001","value":"2.58","spread":"0.669"}]}]}]},{"type":"SECONDARY","title":"Adverse Events","description":"Incidence of adverse events such as itching, redness, inflammation etc","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":12},"commonTop":["scalp itching","scalp dryness","headache"]}}}